The pre-transplant anemic condition is independent of long-term outcome in living-related kidney transplantation

Figures & data

Table 1. Demographic data of included patients.

	Pre-transplant Hb < 10 g/dL	Pre-transplant Hb ≥ 10 g/dL	p
Donor gender (male/female)	139/283	94/186	0.957
Donor age (year)	46.10 ± 10.06	45.47 ± 9.71	0.41
Donor serum creatinine (μmol/L)	102.59 ± 19.58	102.92 ± 21.08	0.832
Recipient gender (male/female)	311/110	217/64	0.326
Recipient age (year)	32.78 ± 8.69	33.01 ± 8.99	0.731
BMI of recipient (kg/m^2)	21.41 ± 2.80	21.37 ± 2.97	0.887
Dialysis period (months)	7.41 ± 10.14	11.36 ± 13.01	<0.001
Recipient pre-transplant  hemoglobin (g/dL)	78.30 ± 14.18	116.2 ± 14.43	<0.001
Erythropoiesis-stimulating  agent (yes/no)	375/47	57/223	0.001
Iron supplement (yes/no)	368/54	46/234	<0.001
Previous transplantation (yes/no)	3/419	5/275	0.189
HLA mismatch
0	33	18
1	22	21
2	90	62
3	218	123	0.104
4	28	34
5	24	19
6	7	3
Panel reactice antibody (%)
0	368	245
1–20%	37	24	0.948
≥20%	16	12
Induction therapy
No	345	231
Anti-CD25 monoclonal antibody	48	35	0.561
ATG	29	14
Cacineurin inhibitor
TAC	246	181
CsA	129	71	0.232
CsA converted to TAC	47	28

Notes: BMI, body mass index; HLA, human leukocyte antigen; ATG, anti-human thymocyte immunoglobulin; TAC, tacrolimus; CsA, cyclosporin A.

Figure 1. Cumulative patient survival in Hb < 10 g/dL versus Hb ≥ 10 g/dL group after transplantation.

Figure 2. Death censored renal allograft survival in Hb < 10 g/dL versus Hb ≥ 10 g/dL group after transplantation.

Figure 3. The first acute rejection episodes in Hb < 10 g/dL versus Hb ≥ 10 g/dL group after kidney transplantation.